Shots:
- The US FDA has approved Roche’s Lunsumio VELO (mosunetuzumab) as an SC formulation for the treatment of adults with r/r follicular lymphoma (FL) after ≥2L of systemic therapy, under accelerated approval
- Approval was based on the P-I/II (GO29781) study in third-line or later FL pts, where Lunsumio VELO demonstrated an ORR of 75% and a CR rate of 59% with an mDoR of 22.4mos.
- Lunsumio VELO also reduced administration time to ~1 min via SC injection vs 2-4 hrs. with IV infusion
Ref: Roche | Image: Roche | Press Release
Related News: Roche Reports P-III (lidERA Breast Cancer) Trial Data on Giredestrant for Early Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
